adenine has been researched along with Acute Liver Injury, Drug-Induced in 23 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Renal toxicity is a concern in patients with chronic hepatitis B taking nucleotide analogues, such as adefovir (ADV) and tenofovir disoproxil fumarate (TDF)." | 7.96 | Long-term Nucleotide Analogue Treatment Has Higher Levels of Renal Toxicities than Does Entecavir in Patients with Chronic Hepatitis B. ( Chang, Y; Cho, EJ; Cho, H; Cho, YY; Kim, YJ; Lee, JH; Nam, JY; Yoon, JH; Yu, SJ, 2020) |
| "Renal toxicity is a concern in patients with chronic hepatitis B taking nucleotide analogues, such as adefovir (ADV) and tenofovir disoproxil fumarate (TDF)." | 3.96 | Long-term Nucleotide Analogue Treatment Has Higher Levels of Renal Toxicities than Does Entecavir in Patients with Chronic Hepatitis B. ( Chang, Y; Cho, EJ; Cho, H; Cho, YY; Kim, YJ; Lee, JH; Nam, JY; Yoon, JH; Yu, SJ, 2020) |
| " Twelve subjects in the QD Group (14%) discontinued treatment due to adverse events, mainly nevirapine-related hepatitis (6%)." | 2.71 | Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach. ( Burger, D; Clotet, B; Galindos, MJ; Gel, S; Miralles, C; Moltó, J; Muñoz-Moreno, JA; Negredo, E; Pedrol, E; Puig, J; Ribera, E; Rodriguez Fumaz, C; Rodríguez, E; Ruiz, L; Viciana, P; Videla, S, 2004) |
| "Limited published real-world data describe adverse events (AEs) among patients treated for mantle-cell lymphoma (MCL)." | 1.62 | Adverse Events and Economic Burden Among Patients Receiving Systemic Treatment for Mantle Cell Lymphoma: A Real-World Retrospective Cohort Study. ( Byfield, SD; Kabadi, SM; LE, L; Olufade, T, 2021) |
| " Its poor oral bioavailability leads to frequent administration causing severe adverse effects." | 1.56 | Stabilized oral nanostructured lipid carriers of Adefovir Dipivoxil as a potential liver targeting: Estimation of liver function panel and uptake following intravenous injection of radioiodinated indicator. ( Abd El-Halim, SM; Abdelbary, GA; Amin, MM; Ibrahim, AB; Shamsel-Din, HA; Zakaria, MY, 2020) |
| "Chloroform is a common contaminant in the drinking water." | 1.48 | 3-methyadenine attenuates chloroform-induced hepatotoxicity via autophagy activation. ( Chen, C; Li, X; Wang, L, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (26.09) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (21.74) | 29.6817 |
| 2010's | 9 (39.13) | 24.3611 |
| 2020's | 3 (13.04) | 2.80 |
| Authors | Studies |
|---|---|
| Fourches, D | 1 |
| Barnes, JC | 1 |
| Day, NC | 1 |
| Bradley, P | 1 |
| Reed, JZ | 1 |
| Tropsha, A | 1 |
| Warner, DJ | 1 |
| Chen, H | 1 |
| Cantin, LD | 1 |
| Kenna, JG | 1 |
| Stahl, S | 1 |
| Walker, CL | 1 |
| Noeske, T | 1 |
| Abd El-Halim, SM | 1 |
| Abdelbary, GA | 1 |
| Amin, MM | 1 |
| Zakaria, MY | 1 |
| Shamsel-Din, HA | 1 |
| Ibrahim, AB | 1 |
| Kabadi, SM | 1 |
| Byfield, SD | 1 |
| LE, L | 1 |
| Olufade, T | 1 |
| Wang, L | 1 |
| Li, X | 1 |
| Chen, C | 1 |
| Tan, R | 1 |
| Tian, H | 1 |
| Yang, B | 1 |
| Zhang, B | 1 |
| Dai, C | 1 |
| Han, Z | 1 |
| Wang, M | 2 |
| Li, Y | 1 |
| Wei, L | 1 |
| Chen, D | 1 |
| Wang, G | 1 |
| Yang, H | 1 |
| He, F | 1 |
| Chen, Z | 1 |
| Cho, YY | 1 |
| Chang, Y | 1 |
| Nam, JY | 1 |
| Cho, H | 1 |
| Cho, EJ | 1 |
| Lee, JH | 1 |
| Yu, SJ | 1 |
| Yoon, JH | 1 |
| Kim, YJ | 1 |
| Echenique, IA | 1 |
| Rich, JD | 1 |
| Mandala, J | 1 |
| Nanda, K | 1 |
| De Baetselier, I | 1 |
| Deese, J | 1 |
| Lombaard, J | 1 |
| Owino, F | 1 |
| Malahleha, M | 1 |
| Manongi, R | 1 |
| Taylor, D | 1 |
| Van Damme, L | 1 |
| Tuma, P | 1 |
| Vispo, E | 1 |
| Barreiro, P | 1 |
| Soriano, V | 1 |
| Ribera Pascuet, E | 1 |
| Curran, A | 1 |
| Ortu, F | 1 |
| Weimer, LE | 1 |
| Floridia, M | 1 |
| Manconi, PE | 1 |
| Ni, HM | 1 |
| Bockus, A | 1 |
| Boggess, N | 1 |
| Jaeschke, H | 1 |
| Ding, WX | 1 |
| Schouten, JN | 1 |
| Van der Ende, ME | 1 |
| Koëter, T | 1 |
| Rossing, HH | 1 |
| Komuta, M | 1 |
| Verheij, J | 1 |
| van der Valk, M | 1 |
| Hansen, BE | 1 |
| Janssen, HL | 1 |
| Negredo, E | 1 |
| Moltó, J | 1 |
| Muñoz-Moreno, JA | 1 |
| Pedrol, E | 1 |
| Ribera, E | 1 |
| Viciana, P | 1 |
| Galindos, MJ | 1 |
| Miralles, C | 1 |
| Burger, D | 1 |
| Rodriguez Fumaz, C | 1 |
| Puig, J | 1 |
| Gel, S | 1 |
| Rodríguez, E | 1 |
| Videla, S | 1 |
| Ruiz, L | 1 |
| Clotet, B | 1 |
| Girault, V | 1 |
| Lattuada, E | 1 |
| Lanzafame, M | 1 |
| Carolo, G | 1 |
| Gottardi, M | 1 |
| Concia, E | 1 |
| Vento, S | 1 |
| Tuchweber, B | 2 |
| Salas, M | 2 |
| Kovacs, K | 2 |
| Garg, BD | 2 |
| Belloni, AS | 1 |
| Rebuffat, P | 1 |
| Neri, G | 1 |
| Mazzocchi, G | 1 |
| Meneghelli, V | 1 |
| Nussdorfer, GG | 1 |
| Molnar, JJ | 1 |
| Riede, UN | 2 |
| Widmer, A | 1 |
| Rohr, HP | 2 |
| Widmer, AE | 1 |
| Bianchi, L | 1 |
| Molnar, J | 1 |
| Khandekar, JD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 3, Multi-center, Double-blind, Randomized, Placebo-controlled Effectiveness and Safety Study to Assess the Role of Truvada® in Preventing HIV Acquisition in Women[NCT00625404] | Phase 3 | 2,120 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
CD4+ T-cell Count at the Time of HIV Seroconversion through 16 weeks (NCT00625404)
Timeframe: Up to 16 weeks
| Intervention | cells/mL (Mean) |
|---|---|
| Truvada Arm | 579.3 |
| Placebo Arm | 601.4 |
Repeat specimens were collected to confirm chemistry toxicities. Grade 2 or higher serum creatinine toxicity was defined as ≥1.4 times the upper limit of normal (NCT00625404)
Timeframe: cumulative toxicity through 52 weeks of product use and 4 weeks post product
| Intervention | participants (Number) |
|---|---|
| Truvada Arm | 4 |
| Placebo Arm | 2 |
Grade 3 or higher ALT elevation was defined as ≥ 2.6 times the upper limit of normal (NCT00625404)
Timeframe: Through 52 weeks on product and 4 weeks post-product
| Intervention | participants (Number) |
|---|---|
| Truvada Arm | 6 |
| Placebo Arm | 8 |
Grade 3 or higher AST elevation was defined as ≥ 2.6 times the upper limit of normal (NCT00625404)
Timeframe: Through 52 weeks on product and 4 weeks post-product
| Intervention | participants (Number) |
|---|---|
| Truvada Arm | 3 |
| Placebo Arm | 1 |
Repeat specimens were collected to confirm chemistry toxicities. Grade 3 phosphorus reduction was defined as ≤2.4mg/dL (NCT00625404)
Timeframe: Through 52 weeks on product and 4 weeks post-product
| Intervention | participants (Number) |
|---|---|
| Truvada Arm | 45 |
| Placebo Arm | 40 |
The total number of adverse events in the placebo and Truvada arms during and within 4 weeks after study product administration. (NCT00625404)
Timeframe: 10-26 months per site
| Intervention | Number of adverse events (Number) |
|---|---|
| Truvada Arm | 2257 |
| Placebo Arm | 2384 |
"Genotypic resistance to FTC and/or tenofovir at the time of HIV diagnosis and 4 weeks later. If resistance was present, testing was repeated at weeks 12, 24, 36 and 52 as necessary (resistance testing will stop if no resistance is detected).~participants were classified as having resistance if they had one or more visits in which resistance was detected, even if the resistance became undetectable over time." (NCT00625404)
Timeframe: up to 52 weeks
| Intervention | participants (Number) |
|---|---|
| Truvada Arm | 3 |
| Placebo Arm | 1 |
HIV Seroconversion, with time to infection refined based on PCR results obtained from stored specimens. (NCT00625404)
Timeframe: Cumulative HIV infection between enrollment and 52 weeks
| Intervention | participants (Number) |
|---|---|
| Truvada Arm | 33 |
| Placebo Arm | 35 |
Difference in mean number of reported sexual partners between final study visit and enrollment visit (NCT00625404)
Timeframe: Up to 52 weeks
| Intervention | mean number of sexual partners (Mean) |
|---|---|
| Truvada Arm | -0.14 |
| Placebo Arm | -0.13 |
Pill counts and participant report of adherence to once-daily pill taking reported as mean days study product could have been used according to pill counts (NCT00625404)
Timeframe: Up to 52 weeks
| Intervention | percentage of days (Mean) |
|---|---|
| Truvada Arm | 87 |
| Placebo Arm | 89 |
Viral load at the time of HIV detection, HIV conversion and through 16 weeks (NCT00625404)
Timeframe: up to 16 weeks
| Intervention | log copies/mL (Log Mean) |
|---|---|
| Truvada Arm | 4.40 |
| Placebo Arm | 4.37 |
Reported complications during pregnancy, including spontaneous abortion, vaginal or uterine bleeding, emergency c-section and other complications (NCT00625404)
Timeframe: up to 60 weeks
| Intervention | participants (Number) |
|---|---|
| Truvada Arm | 20 |
| Placebo Arm | 10 |
4 reviews available for adenine and Acute Liver Injury, Drug-Induced
| Article | Year |
|---|---|
EFV/FTC/TDF-associated hepatotoxicity: a case report and review.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 L | 2013 |
[Role of tenofovir in HIV and hepatitis C virus coinfection].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Chemical and Drug | 2008 |
[Current role of tenofovir in clinical medicine].
Topics: Adenine; Anti-HIV Agents; Antimetabolites; Antiretroviral Therapy, Highly Active; Chemical and Drug | 2008 |
[The treatment of HIV infection].
Topics: Adenine; Anti-Retroviral Agents; Carbamates; Chemical and Drug Induced Liver Injury; Clinical Trials | 2005 |
2 trials available for adenine and Acute Liver Injury, Drug-Induced
| Article | Year |
|---|---|
Liver and renal safety of tenofovir disoproxil fumarate in combination with emtricitabine among African women in a pre-exposure prophylaxis trial.
Topics: Adenine; Adolescent; Adult; Alanine Transaminase; Anti-HIV Agents; Aspartate Aminotransferases; Blac | 2014 |
Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-CD8 Ratio; Chemical and Drug Induced Live | 2004 |
17 other studies available for adenine and Acute Liver Injury, Drug-Induced
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLI | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters | 2012 |
Stabilized oral nanostructured lipid carriers of Adefovir Dipivoxil as a potential liver targeting: Estimation of liver function panel and uptake following intravenous injection of radioiodinated indicator.
Topics: Adenine; Administration, Oral; Animals; Chemical and Drug Induced Liver Injury; Drug Stability; Inje | 2020 |
Adverse Events and Economic Burden Among Patients Receiving Systemic Treatment for Mantle Cell Lymphoma: A Real-World Retrospective Cohort Study.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydro | 2021 |
3-methyadenine attenuates chloroform-induced hepatotoxicity via autophagy activation.
Topics: Adenine; Animals; Autophagy; Chemical and Drug Induced Liver Injury; Chloroform; Cytokines; Disease | 2018 |
Autophagy and Akt in the protective effect of erythropoietin helix B surface peptide against hepatic ischaemia/reperfusion injury in mice.
Topics: Adenine; Animals; Autophagosomes; Autophagy; Cell Line; Chemical and Drug Induced Liver Injury; Chro | 2018 |
Long-term Nucleotide Analogue Treatment Has Higher Levels of Renal Toxicities than Does Entecavir in Patients with Chronic Hepatitis B.
Topics: Adenine; Adult; Aged; Antiviral Agents; Chemical and Drug Induced Liver Injury; Female; Glomerular F | 2020 |
Raltegravir, tenofovir, and emtricitabine in an HIV-infected patient with HCV chronic hepatitis, NNRTI intolerance and protease inhibitors-induced severe liver toxicity.
Topics: Adenine; Adult; Antiviral Agents; CD4-Positive T-Lymphocytes; Chemical and Drug Induced Liver Injury | 2010 |
Activation of autophagy protects against acetaminophen-induced hepatotoxicity.
Topics: Acetaminophen; Acetylcysteine; Adenine; Analgesics, Non-Narcotic; Animals; Autophagy; Chemical and D | 2012 |
Risk factors and outcome of HIV-associated idiopathic noncirrhotic portal hypertension.
Topics: Adenine; Adult; Anti-HIV Agents; Case-Control Studies; Chemical and Drug Induced Liver Injury; Didan | 2012 |
Does tenofovir increase efavirenz hepatotoxicity?
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Chemi | 2008 |
Prevention of CeCl3-induced hepatotoxicity by hypolipidemic compounds.
Topics: Adenine; Animals; Cesium; Chemical and Drug Induced Liver Injury; Cholesterol; Clofibrate; Female; H | 1978 |
Effect of cerium on the rat liver: an ultrastructural and biochemical study.
Topics: Adenine; Adenosine Triphosphate; Alanine Transaminase; Animals; Bilirubin; Cell Nucleus; Cerium; Che | 1976 |
Effects of 4-aminopyrazolo (3,4-d) pyrimidine on rat hepatocytes: an ultrastructural morphometric study.
Topics: Adenine; Animals; Anticholesteremic Agents; Chemical and Drug Induced Liver Injury; Cholesterol; End | 1989 |
[Adenine induced liver parenchymal cell injury].
Topics: Adenine; Animals; Chemical and Drug Induced Liver Injury; Liver; Liver Diseases; Male; Microscopy, E | 1970 |
[Ultrastructural-morphometric study on rat liver parenchymal cells in acute adenine poisoning].
Topics: Adenine; Animals; Chemical and Drug Induced Liver Injury; Endoplasmic Reticulum; Golgi Apparatus; In | 1971 |
Beloxamide effects on the liver ultrastructure in rats.
Topics: Acetamides; Adenine; Animals; Benzyl Compounds; Chemical and Drug Induced Liver Injury; Cytoplasm; E | 1971 |